Prostate Cell News Volume 5.45 | Nov 28 2014

The Long Non-Coding RNA PCAT-1 Promotes Prostate Cancer Cell Proliferation through cMyc12
Researchers describe a role for the oncogenic long non-coding RNAs PCAT-1 in prostate cancer proliferation through cMyc. They found that PCAT-1-mediated proliferation is dependent on cMyc protein stabilization, and using expression profiling, they observed that cMyc is required for a subset of PCAT-1-induced expression changes. [Neoplasia] Full Article

Hsp90 C-Terminal Inhibitors Exhibit Anti-Migratory Activity by Disrupting the Hsp90α/Aha1 Complex in PC3-MM2 Cells
Scientists report that Hsp90α associates with the Aha1 co-chaperone and found this complex to localize in secretory vesicles and at the leading edge of migrating cells. Knockdown of Hsp90α resulted in a defect in cell migration. [ACS Chem Biol] Abstract

Prostate Cancer Cells Induce Osteoblastic Differentiation via Semaphorin 3A
Researchers investigated whether prostate cancer cells can mediate osteoblastic activity through semaphorin 3A (Sema 3A). They cultured osteoprogenitor MC3T3-E1 cells in prostate cancer-conditioned medium, and analyzed levels of Sema 3A protein in diverse prostate cancer cell lines to identify cell lines in which Sema 3A production showed a positive correlation with osteo-stimulation. [Prostate] Abstract

[¹⁸F]Fluoromethylcholine as a Chemotherapy Response Read-Out in Prostate Cancer Cells
The effects of docetaxel and cabazitaxel on viable tumor cell number were explored in four prostate cancer cell lines. Cellular uptake of 2-deoxy-2-[¹⁸F]fluoro-D-glucose and [¹⁸F]fluoromethylcholine was compared with the effects measured using sulforhodamine B assay, cell counting and colony formation assay, as proximators of viable tumor cell number. [Mol Imaging Biol] Abstract

MicroRNA-224 and Its Target CAMKK2 Synergistically Influence Tumor Progression and Patient Prognosis in Prostate Cancer
Calcium/calmodulin-dependent protein kinase kinase 2 (CAMKK2) was identified as a target gene of microRNA (miR)-224. Then, scientists found that enforced expression of miR-224 could suppress prostate cancer cell proliferation and cell cycle by regulating the expression of CAMKK2 in vitro. [Tumor Biol] Abstract

Boric Acid Induces Cytoplasmic Stress Granule Formation, eIF2α Phosphorylation, and ATF4 in Prostate DU-145 Cells
Scientists report that treatment of DU-145 prostate cells with physiological levels of boric acid induces endoplasmic reticulum stress with the formation of stress granules and mild activation of eIF2α, GRP78/BiP, and ATF4. [Biometals] Full Article

CLINICAL RESEARCH

Denosumab for the Prevention of Skeletal Complications in Metastatic Castration-Resistant Prostate Cancer: Comparison of Skeletal-Related Events and Symptomatic Skeletal Events
In a Phase III trial in patients with castration-resistant prostate cancer and bone metastases, denosumab was superior to zoledronic acid in reducing skeletal-related events. Researchers reassessed the efficacy of denosumab using symptomatic skeletal events as a prespecified exploratory endpoint. [Ann Oncol]
Abstract | Full Article

Bevacizumab and the Risk of Arterial and Venous Thromboembolism in Patients with Metastatic, Castration-Resistant Prostate Cancer Treated on Cancer and Leukemia Group B (CALGB) 90401 (Alliance)
The authors investigated the association of bevacizumab treatment and clinical factors with arterial thromboembolism/venous thromboembolism risk in patients who were treated on Cancer and Leukemia Group B (CALGB) trial 90401. Patients with metastatic, castration-resistant prostate cancer were randomized to receive docetaxel and prednisone with or without bevacizumab once every 21 days. [Cancer] Abstract

Visit our reviews page to see a complete list of reviews in the prostate cell research field.

New Ontario Institute to Tackle Costly Diseases of Aging
The Government of Ontario has awarded new funding to the Ontario Stem Cell Initiative and the Centre for Commercialization of Regenerative Medicine to establish the Ontario Institute for Regenerative Medicine – a research, development and commercialization institute dedicated to the translation of stem cell research into curative therapies for major degenerative diseases. [Ontario Institute for Regenerative Medicine (Marketwire L.P.)] Press Release

From our sponsor: Pluripotent cell isolation for regenerative medicine. Request a free wallchart from Nature.

Food and Drug Administration (United States)

Center for Biologics Evaluation and Research (United States)

European Medicines Agency (European Union)

Medicines and Healthcare Products Regulatory Agency (United Kingdom)

Therapeutic Goods Administration (Australia)

Visit our events page to see a complete list of events in the prostate cell community.

NEW Postdoctoral Scientist – Prostate Oncobiology (Cancer Research UK Manchester Institute)

Postdoctoral Researcher – Chromatin and Epigenetic Regulation (Van Andel Research Institute)

Associate Professor – Physiology (University of Bergen)

Postdoctoral Position – Prostate Cancer (Roswell Park Cancer Institute)

Postdoctoral Position – Prostate Cancer and Prostatic Diseases (Louisiana State University)

Postdoctoral Associate – Biomarkers Associated with Prostate Cancer (Duke Molecular Physiology Institute)

Head of Cellular and Molecular Therapies Laboratory (NHS Blood & Transplant)

Postdoctoral Fellow – Metabolomics and Prostate Cancer (University of Maryland)

Postdoctoral Fellow – Role of Deregulated PTEN/FOXO1 Pathway in Prostate Cancer (Mayo Clinic)

Postdoctoral Fellow – Oncology (Johnson & Johnson Pharmaceutical Research & Development)

Postdoctoral Fellow – Prognostic Biomarkers for Prostate Cancer (McGill University)

Tenure Track Position – Cancer Biology (Wake Forest Baptist Medical Center)

Scientist – Prostate Cell Research (STEMCELL Technologies Inc.)

Scientist – Cell Culture Support Products (STEMCELL Technologies Inc.)

Scientist – Immunology/Cell Separation (STEMCELL Technologies Inc.)

Recruit Top Talent: Reach more than 50,000 potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.